Provide feedbackProvide feedback

Home :: Neurology

New cognitive screening test seems more sensitive to detection of AD, easier to administer than MMSE, data suggest

Wednesday, June 24 2009 | Comments
Evidence Grade 2 What's This?

A new cognitive screening test developed by researchers at Addenbrooke's Hospital in the United Kingdom is easier to administer than the Mini-Mental State Examination (MMSE) and has greater sensitivity for the detection of Alzheimer's disease (AD), according to findings from a cross-sectional study. The researchers designed the tool, which is called Test Your Memory (TYM), to be suitable for widespread use, even by nonspecialists. Specifically, they wanted to create a screening test that...

A new cognitive screening test developed by researchers at Addenbrooke's Hospital in the United Kingdom is easier to administer than the Mini-Mental State Examination (MMSE) and has greater sensitivity for the detection of Alzheimer's disease (AD), according to findings from a cross-sectional study.

The researchers designed the tool, which is called Test Your Memory (TYM), to be suitable for widespread use, even by nonspecialists. Specifically, they wanted to create a screening test that requires minimal operator time to administer, assesses a reasonable range of cognitive functions, and is sensitive to the detection of mild AD. Although the MMSE has been the standard short cognitive test for decades, it does not satisfy these 3 critical requirements, they noted.

The TYM is filled out by patients, with healthy control subjects completing it in approximately 5 minutes, according to data from the current study. It includes 10 tasks (orientation, ability to copy a sentence, semantic knowledge, calculation, verbal fluency, similarities, naming, 2 tasks evaluating visuospatial abilities, and recall of a copied sentence). Scores for these tests, along with a score reflecting the patient's ability to complete the test, are combined for a maximum possible score of 50.

To evaluate the TYM's usefulness in the detection of AD, the investigators recruited 679 subjects to complete the TYM as well as Addenbrooke's cognitive examination, which contains the MMSE. The participants included 94 subjects with AD, 14 subjects with amnestic mild cognitive impairment (MCI), 31 subjects with non-AD degenerative dementia, and 540 healthy controls.

In an analysis of the 94 patients with AD and 282 age-matched controls, the mean TYM score was 33.2 among the patients with AD, compared with a score of 46.6 among the controls (P<.001). After correction for multiple comparisons, differences between the cases and controls were significant for all subtests, except for sentence copying. The authors added that TYM scores, Addenbrooke scores, and MMSE scores were strongly and significantly correlated in the patients with AD (P<.001 for all 3 correlations).

A score of <=42 had a sensitivity of 93% for detecting AD, compared with a sensitivity of 52% with the MMSE. The specificity at this cutoff was 86%. The negative predictive value (NPV) of a TYM score of <=42 was 100% in a population with an AD prevalence of up to 5%; the positive predictive value (PPV) was 26%. The NPV and PPV of a TYM score of <=42 were 99% and 42%, respectively, in a population with an AD prevalence of 10%.

A score of >=43 correctly excludes a diagnosis of AD in 97% of cases even when the prevalence of AD within a population is as high as 30%, the researchers noted. Given the high NPV with this cutoff, they suggested that the TYM might be a valuable screening test for memory problems.

The low PPV, particularly in unselected groups, indicates that the TYM cannot be used alone to diagnose AD, although the authors noted that the PPV would be higher in select groups with a higher disease prevalence, such as older adults with memory complaints.

Among the 31 patients with non-AD dementia, the average TYM score (38.9) was below the cutoff for dementia (<=42). By contrast, the average MMSE score was 25.3, which was greater than the standard cutoff for dementia with this test (<=23), suggesting that the TYM was superior to the MMSE for the diagnosis of non-AD dementia. (Brown J, et al. BMJ 2009;338:b2030.)

Latest News

Substitution of Topamax with multiple generic formulations associated with greater health care costs, increased risk of hospitalization, injuries, findings suggest Verusmed

Wednesday, June 24 2009 | Comments
Evidence Grade 3 What's This?
Patients with epilepsy who use multiple generic formulations of topiramate seem to incur higher health care costs and have higher rates of hospitalizations and injuries relative to patients who use the brand-name version of the drug (Ortho-McNeil-Janssen Pharmaceuticals Inc.'s Topamax), according to findings from a retrospective study.

The study researchers noted that there is concern among physicians regarding generic...
Tags: Epilepsy


Phase II data show potential benefit of memantine for patients with PD dementia, dementia with Lewy bodies Verusmed

Wednesday, June 24 2009 | Comments
Evidence Grade 2 What's This?
Patients with Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB) seem to benefit from treatment with memantine hydrochloride, according to findings from a Phase II trial conducted in Norway, Sweden, and the United Kingdom.

Researchers randomized 72 patients with mild to moderate PDD or DLB to receive memantine (n=34; maintenance dose, 20 mg/day) or placebo (n=38) for 24 weeks. The primary outcome measure was the Clinical Global Impression of Change (CGIC)...
Tags: Alzheimer's Disease & Dementia


Addition of memantine to cholinesterase inhibitor therapy significantly delays time to nursing home admission, observational data suggest Verusmed

Wednesday, June 10 2009 | Comments
Evidence Grade 3 What's This?
Combination therapy with memantine hydrochloride and a cholinesterase inhibitor significantly delays time to nursing home admission relative to cholinesterase inhibitor use alone, according to an analysis conducted at the University of Pittsburgh.

Researchers reviewed data for 943 individuals with probable Alzheimer's disease, all of whom received at least a 1-year follow-up evaluation through their participation in the Alzheimer's Research...

Modifiable lifestyle factors predict maintenance of cognitive function in older adults, findings indicate Verusmed

Wednesday, June 10 2009 | Comments
Evidence Grade 2 What's This?
Certain variables that predict successful cognitive aging include modifiable lifestyle factors that could be targeted in programs designed to prevent cognitive decline, according to an analysis of data from the Health, Aging, and Body Composition (Health ABC) study.

Researchers evaluated data for 2,509 participants aged 70 to 79 years at enrollment. Cognitive function was assessed with the modified Mini-Mental State Examination (MMSE) at baseline and during years 3, 5, and 8 of...
Tags: Alzheimer's Disease & Dementia






Neurology Conference Coverage